John Adams, MD
Urology · Charleston, SCNPI 1013081678
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $10,462 of the $14,686 with a category attached, or 71.2%. Boston Scientific accounts for 73.8% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2019 at $3,745 and has fallen 88.7% since, to $423 in 2025.
Across 154 payments — averaging $95.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$11K
- Procept Biorobotics Corporation$1K
- Arthrex$323
- Teleflex LLC$318
- Olympus America Inc.$228
- AbbVie$183
- plus $2K from 31 others
What the payments were for
- Royalty or licence$10,46271%
- Travel & lodging$8005%
- Food & beverage$3,40023%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 37 | $10,832 |
| Procept Biorobotics Corporation | 7 | $1,191 |
| Arthrex | 2 | $323 |
| Teleflex LLC | 10 | $318 |
| Olympus America Inc. | 6 | $228 |
| AbbVie(2 entities) | 12 | $183 |
| Boehringer Ingelheim | 13 | $181 |
| Calyxo, Inc. | 1 | $144 |
| Astellas Pharma US Inc | 8 | $124 |
| Coloplast | 5 | $99 |
| Myovant Sciences Inc. | 5 | $97 |
| Avanos Medical | 1 | $95 |
| Dentsply IH Inc. | 4 | $75 |
| Neotract Inc. | 2 | $74 |
| Accord Healthcare, Inc. | 4 | $65 |
| Merck | 3 | $53 |
| Therapeuticsmd, Inc. | 3 | $51 |
| AstraZeneca | 3 | $50 |
| Urogen Pharma, Inc. | 2 | $45 |
| Bayer | 3 | $43 |
| Johnson & Johnson(2 entities) | 2 | $43 |
| Abbott | 2 | $42 |
| ABC Home Medical Supply, Inc. | 2 | $37 |
| Convatec Inc. | 2 | $35 |
| Pfizer | 2 | $30 |
| Urovant Sciences Inc | 2 | $28 |
| Verity Pharmaceuticals Inc. | 1 | $25 |
| Tolmar Pharmaceuticals, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Myriad Genetic Laboratories, Inc. | 1 | $18 |
| Ambu Inc. | 1 | $17 |
| Cook Medical LLC | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $15 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $13 |
| Sagent Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$6,130
- AMPLATZ$1,579
- PERCUFLEX$1,516
- AquaBeam Robotic System$775
- AQUABEAM SYSTEM$362
- CLEAR RENAL SHEATH$347
- CVAC Aspiration System$144
- rezum Generator$129
- UroLift$117
How this compares
$14,686 in reported general payments places this provider in the 85th percentile of 196 urology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 52 | $38,900 |
| GemtesaVibegron | 22 | $11,109 |
| Tamsulosin Hcl | 286 | $3,988 |
| Methenamine Hippurate | 50 | $3,875 |
| Tadalafil | 61 | $3,488 |
| Estradiol | 28 | $2,126 |
| Solifenacin Succinate | 40 | $1,674 |
| Finasteride | 54 | $681 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $611 |
| Dutasteride | 12 | $558 |
| Oxybutynin Chloride | 35 | $449 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 24 | $378 |
| Ciprofloxacin Hcl | 43 | $163 |
| Cephalexin | 13 | $115 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $124 | $38,90052 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $23 | $11,10922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 196 urology providers in South Carolina.
Other urology in Charleston
- Sandip PrasadCharleston$177K
- Ian MarshallCharleston$60K
- Thomas KeaneCharleston$52K
- Stephen SavageCharleston$32K
- Matvey TsivianCharleston$18K
- John BrittonCharleston$15K
- Bradley SteeleCharleston$12K
- Alexander RamsayCharleston$10K
- Mark BuchananCharleston$8K
- Daniel FurlongCharleston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.